From Discovery to Implementation

Our developmental pipeline enables results from discovery to clinical implementation. From companion diagnostic (CDx) co-development to precision streamlined development and implementation of assays and diagnostic tests, we are here to help support your unique clinical trial and project objectives.

image description

The FYR Benefit

  • Partnerships

    Clinical trial support, biomarker discovery, biomarker validation, translation of tissue markers to plasma, companion diagnostic development

  • Multiomics-First Approach

    Leveraging the power of DNA, RNA, and Protein data from Extracellular Vesicles for comprehensive multiomics insights of biology and disease

  • Experience

    Extracellular Vesicle-focused company with extensive experience in EVs and their various applications to understand diseases with unmet clinical needs

Why Choose FYR?

Our expertise in Extracellular Vesicles (EVs) and operations in a CLIA-certified lab enable us to tackle challenges that organizations have when developing or deploying a therapy. Aware of various factors contributing to trial failures, such as the critical issue of unsuitable patient selection, we employ our multiomics workflows and comprehensive understanding of disease pathways and drug interactions. Partnering with FYR has the potential to increase trial success rates and yield more accurate outcomes, with our team’s experience and EV technologies driving research objectives and clinical strategy optimization. 

  • Novel Technologies

    • EVO-Platform™: Comprehensive multiomics approach, combining genomics, transcriptomics, and proteomics data to reveal disease and biomarker insights. Focus on EVs for advanced disease detection and monitoring through both liquid and traditional tissue biopsies.
    • SPARCs™: Selective Protein Affinity Reagent Chemistries, designed to isolate specific disease or tissue-associated EV subpopulations, enriching vital biomarkers for more accurate and early disease detection.
    • Advanced Machine Learning & Analytics.
  • Helping Answer Your Questions

    • Pathways associated with my disease of interest and drug target?
    • Better subset of patients suitable more suitable for my drug?
    • Markers that can monitor patient response and disease progression?

FYRed Up About Partnering With Us?

Have we sparked your interest in partnering with us? We fuel new relationships, collaborations, and strategic partnerships. Let’s kindle the next generation of innovation together. To learn more about our services or to receive a quote, contact us.

Contact us